首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 在线期刊 2004年 => 5期 =>苦参素治疗乙肝所致肝纤维化的临床..
苦参素治疗乙肝所致肝纤维化的临床观察
Clinial efficacy of kwoninone in the treatment hepatic fibrosis with hepatitis B virus
文章发布日期:2009年10月15日  来源:  作者:彭安邦; 姚育红; 谢黎明; 钱贤  点击次数:1647次  下载次数:574次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:观察苦参素治疗乙肝所致肝纤维化的作用。苦参素治疗肝纤维化患者前后检测血清肝纤维化四项指标与乙肝病毒标志物 ,并与γ -干扰素对照。LN、HA、Pc -Ⅲ、Ⅳ -C在苦参素治疗前后有显著性差异 (P <0 0 1,P<0 0 5 ) ;与γ -干扰素组比较无显著差异 (P <0 5 ,P <0 2 5 ) ,说明两者疗效相仿。苦参素治疗组HBsAg、HBeAg与HBV -DNA转阴率分别是 3 3%、2 2 8%、2 0 0 % ,略低于γ -干扰素组 ,但两组比较无显著性差异 (P >0 5 ,P >0 75 )。苦参素是治疗肝纤维化与抗乙肝病毒有效的药物之一
【Abstract】:To study clinical efficacy of kwoninone in the treatment patients with hepatic fibrosis and hepatitis B virus. Sixty patients were divided randomly into the treated group(kwoninone, 30 cases)and the controlled group(γ-interferon, 30 cases). Four marks of hepatic fibrosis(laminin、hyaluronic acid、type Ⅲ procollagen peptide、type Ⅳ collagen) and markers of hepatitis B virus (HBsAg、HBeAg and HBV-DNA) were determined before and after treatment. Four marks of hepatic fibrosis were obviously reduced in two groups after treatment. No different significantly was found between two groups (P<0.5,P<0.25). The result showed that the two drugs have the same curative effect in the treatment patients with hepatic fibrosis. HBsAg、HBeAg、HBV-DNA negative conversion rats of the treated group were 3.3%、22.8%、20.0% respectively. They were slightly lower than that in the controled group. The negative conversion rats of the two groups were not different significantly (P>0.5,P>0.75). Kwoninone may b
【关键字】:苦参素; γ-干扰素; 肝纤维化; 乙肝病毒标志物
【Key words】:kwoninone; γ-interferon; hepatic fibrosis; hepatitis B virus
【引证本文】:

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号